

## References

1. Fedorova TA, Himochko TG, Rojzman AP. *Moskovskij medicinskij zhurnal – Moscow Medical Journal* 2001;1:23–25.
2. Kalinichenko YuM, Ostrovskiy MM. *Ukrainskyi pulmonologichnyi zhurnal – Ukrainian pulmonological Journal* 2006;1:33–34.
3. Amosova KM, Konoplova LF, Honza OO, Rudenko YuV. *Ukrainskyi pulmonologichnyi zhurnal – Ukrainian pulmonological Journal* 2008;3(Suppl):51–54.
4. Amosova KM, Konoplova LF, Reshotko DO. *Ukrayinskyi terapevtychnyi zhurnal – Ukrainian Journal of Therapeutics* 2004;4:18–23.
5. Paleev NR, Paleev FN. *Klinicheskaya medicina – Clinical medicine* 2004;5:4–7.
6. Voronkov LH, Amosova KM, Bahriy AE. *Sertseva nedostatnist – Heart failure* 2012;3:60–96.
7. Tereshhenko SN, Pavlikova EP, Meraj IA. *Serdechnaya nedostatochnost* 2003;2:103–104.
8. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. *Am. J. Respir. Cell Mol. Biol* 2003;28:555–562.
9. Atlas SA. The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition. *Journal of Managed Care Pharmacy* 2007;13(8), Suppl B:9–20.
10. Budev MM, Arroliga AC, Wiedemann HP, Matthay RA. Cor pulmonale: an overview. *Seminars in Respiratory and Critical Care Medicine* 2003;24(3):233–244.
11. McMurray JJV, Östergren J, Swedberg K, Granger ChB, Held P, Michelson EL, Olofsson B, Salim Yusuf, Pfeffer MA. *Lancet* 2003;362:767–771.
12. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Kenneth Dickstein, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GYH, PietroMaggioni A, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *European Heart Journal* 2012;33:1787–1847.
13. Brogger J, Steen VM, Eiken HG, Gulsvik A, Bakke P. Genetic association between COPD and polymorphisms in TNF, ADRB2 and EPHX1. *Eur. Respir. J* 2006;27(4):682–688.
14. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease: (Updated 2013) [Електронний ресурс]. Режим доступу: <http://www.goldcopd.org>.
15. A Stephanou, Scarabelli TM, Brar BK, Nakanishi Y, Matsumura M, Knight RA Latchman DS. Induction of apoptosis and Fas receptor/Fas ligand expression by ischemia/reperfusion in cardiac myocytes requires serine 727 of the STAT-1 transcription factor but not tyrosine 701. *J. Biol. Chem* 2001;276 (30):28340–28347.

16. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrandt P, Dargie HJ NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. *Eur. J Heart Failure* 2004;6:269–273.
17. Gan CT, McCann GP, Marcus JT, van Wolferen SA, Twisk JW, Boonstra A, Postmus PE, Vonk-Noordegraaf A. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. *Eur. Respir. J* 2006;28 (6):1190–1194.
18. Vaghasiya NB, Trivedi VR, Chorawala MR. Molecular mechanisms of myocardial remodeling. *Am. J. PharmTech Res* 2012;2 (2):53–74.
19. Wright JL, Kerstjens HA, Timens WP. What is new in chronic obstructive pulmonary disease? *Eur. Resp. Mon* 2007;39:153–169.
20. Wu A, Harrison A, Maisel A. Reduced readmission rate for alternating diagnoses of heart failure and pulmonary disease after implementation of Btype natriuretic peptide testing. *Eur. J. Heart Fail* 2004;6:309–312.